Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

Phase 2

Active, not recruiting

• Conditions: MALT Lymphoma
• Interventions: Drug: Chlorambucil; Drug: Rituximab i.v.; Drug: Rituximab s.c.

• Registration Number: NCT01808599
• Lead Sponsor: International Extranodal Lymphoma Study Group (IELSG)

Brief Summary

Single arm phase II study of Chlorambucil in combination with subcutaneous Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type arisen at any extranodal site, either de novo, or relapsed following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma).

Detailed Description

The study consists in three parts. In Part A (induction phase I) patients will be treated with Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on day 1 week 1 followed by subcutaneous Rituximab 1400mg on days 8, 15 and 22 (day 1 of weeks 2, 3 and 4). After restaging (CT scan to be performed during weeks 7-8, i.e. between d42 and d55), responding patients (CR, CRu, PR) and those with stable disease will be treated in part B (induction phase II). In part B, starting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. After restaging (CT scan to be performed at the end of month 6) responding patients and those with stable disease will be treated in part C. In Part C (maintenance phase) patients will be treated with subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections). During maintenance phase, CT scans will be performed every 12 months and patients responding or with stable disease will stay on treatment for a total of two years as above reported.

Study Timeline

• Study First Submitted: 2013-03-06
• Study First Submitted QC: 2013-03-08
• Study First Posted: 2013-03-11
• Study Start: 2013-12
• Primary Completion: 2016-03
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-27
• Last Update Posted: 2024-08-28
• Study Completion: 2028-09

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 112

Inclusion Criteria

1. Histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type either de novo, or relapsed following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma) arisen at any extranodal site 1.1 The following patients with gastric MALT Lymphoma can be entered:

   • H. pylori-negative cases, either de novo (non pre-treated) or at relapse following local therapy (i.e., surgery, radiotherapy or antibiotics).

   • H. pylori-positive cases at diagnosis, who failed antibiotic therapy, including

     • Patients with clinical (endoscopic) and histological evidence of disease progression at any time post H. pylori eradication
     • Stable disease with persistent lymphoma at ≥ 1 year post H. pylori eradication
     • Relapse (without H. pylori re-infection), after a remission
     • Patients who failed either first line antibiotics or further local treatment (surgery or radiotherapy) 1.2 Similar consideration may be applied to patients with ocular adnexal lymphoma treated with antibiotics.

2. Measurable or evaluable disease. Measurable disease in at least two perpendicular dimensions on an imaging scan is defined as: lymph node or nodal mass bi-dimensional measurement with > 1.5 cm in longest transverse diameter or the short diameter must measure > 10 mm regardless of the longest transverse diameter.

3. Any stage (Ann Arbor I-IV) (see Appendix A)

4. Age ≥ 18

5. Life expectancy of at least 1 year

6. ECOG performance status 0-2 (see Appendix B)

7. Adequate bone marrow function (WBC >3.0x109/L, ANC >1.5x109/L, PLT >100x109/L), unless due to lymphoma involvement

8. Adequate kidney (serum creatinine <1,5x upper normal) and liver function (ASAT/ALAT <2,5 upper normal, total bilirubin <2,5x upper normal), unless due to lymphoma involvement

9. For women of childbearing potential only: negative serum pregnancy test done within 7 days prior to study drugs administration or within 14 days if with a confirmatory urine pregnancy test within 7 days prior to the first study drugs administration

10. Fertile male or female patients of childbearing potential and their partners must use two forms of contraception during the study and for at least 12 months after the last dose of subcutaneous rituximab.

    For appropriate methods of contraception considered acceptable, see Appendix C. Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study and for 12 months after study participation, the patient should inform the treating physician immediately.

    Female patients of childbearing potential are defined as follows:

    • Pre-menopausal women (patients with regular menstruation, patients after menarche with amenorrhea or irregular cycles, patients using a contraceptive method that precludes withdrawal bleeding
    • Women who have had tubal ligation

    Female patients may be considered to NOT be of childbearing potential for the following reasons:

    • The patient has undergone total abdominal hysterectomy with bilateral salpingo-oophorectomy or bilateral oophorectomy
    • The patient is medically confirmed to be menopausal (no menstrual period) for 24 consecutive months

11. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

1. Evidence of histologic transformation to a high grade lymphoma
2. Prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer
3. Prior chemotherapy
4. Prior immunotherapy with any anti-CD20 monoclonal antibody
5. Prior radiotherapy in the last 6 weeks
6. Use of corticosteroids during the last 28 days, unless prednisone chronically administered at a dose <20 mg/day for indications other than lymphoma or lymphoma-related symptoms
7. Evidence of clinically significant cardiac disease, as defined by history of symptomatic ventricular arrhythmias, congestive heart failure or myocardial infarction within 12 months before study entry
8. Evidence of symptomatic central nervous system (CNS) disease
9. Evidence of active opportunistic infections
10. Known HIV infection
11. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HBV DNA test will be performed and if positive the subject will be excluded
12. Positive serology for hepatitis C (HC) defined as a positive test for HCAb, confirmed by HC RIBA immunoblot assay on the same sample.
13. Pregnant or lactating status
14. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
15. Fertile men or women of childbearing potential who do not agree to use a highly effective measure of contraception (such as oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) throughout the study and for at least 12 months after the last dose of subcutaneous rituximab

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Chlorambucil, Rituximab i.v., Rituximab s.c.	Rituximab s.c.	Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on days 1, 8, 15 and 22 (day 1 of weeks 1, 2, 3 and 4). Starting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. Therefore subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections).
Chlorambucil, Rituximab i.v., Rituximab s.c.	Rituximab i.v.	Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on days 1, 8, 15 and 22 (day 1 of weeks 1, 2, 3 and 4). Starting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. Therefore subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections).
Chlorambucil, Rituximab i.v., Rituximab s.c.	Chlorambucil	Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on days 1, 8, 15 and 22 (day 1 of weeks 1, 2, 3 and 4). Starting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. Therefore subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections).

Primary Outcome Measures

Name	Time	Method
Complete remission rate	week 25

Secondary Outcome Measures

Name	Time	Method
Response Rate	week 25	Response rate (Complete and partial remission rates) for all patients
Event-free-survival (EFS)	at 5 years

Trial Locations

Locations (38)

Dijon CHU Hopital le Bocage; 🇫🇷 Dijon, France

Clermont Ferrand CHU Estaing; 🇫🇷 Estaing, France

AO SS. Antonio e Biagio e Cesare Arrigo; 🇮🇹 Alessandria, Italy

Milano Ospedale Policlinico; 🇮🇹 Milano, Italy

UO Ematologia Ravenna; 🇮🇹 Ravenna, Italy

SC Oncoematologia Terni; 🇮🇹 Terni, Italy

Nantes CHU Hotel Dieu; 🇫🇷 Nantes, France

Tours CHU Bretonneau; 🇫🇷 Tours, France

Paris Hopital Saint Louis; 🇫🇷 Paris, France

Biella Ospedale degli Infermi; 🇮🇹 Biella, Italy

Genova Ematologia I H San Martino; 🇮🇹 Genova, Italy

Grenoble CHU Pontchaillou; 🇫🇷 Grenoble, France

Istituto Nazionale dei Tumori, Milano; 🇮🇹 Milano, Italy

Nocera; 🇮🇹 Nocera Umbra, Italy

Marseille Paoli Calmettes; 🇫🇷 Marseille, France

Ematologia Ospedale Businco (Cagliari); 🇮🇹 Cagliari, Italy

ARNAS Garibaldi Catania; 🇮🇹 Catania, Italy

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola; 🇮🇹 Meldola, Italy

IOV Padova; 🇮🇹 Padova, Italy

Ospedale Infermi Ematologia Rimini; 🇮🇹 Rimini, Italy

Istituto Regina Elena, Roma, IFO; 🇮🇹 Roma, Italy

Ancona; 🇮🇹 Ancona, Italy

Ematologia e CTMO Ospedale Bolzano; 🇮🇹 Bolzano, Italy

Azienda Sanitaria AUSL6 Livorno; 🇮🇹 Livorno, Italy

Azienda Ospedaliero-Universitaria di Parma; 🇮🇹 Parma, Italy

Arcispedale Santa Maria Nuova, Azienda Ospedaliera di Reggio Emilia; 🇮🇹 Reggio Emilia, Italy

IRCCS/CROB Rionero in Vulture; 🇮🇹 Rionero in Vulture, Italy

Vandoeuvre lès Nancy CHU Brabois; 🇫🇷 Nancy, France

Créteil Hopital Henri Mondor; 🇫🇷 Créteil, France

Pierre Bénite CHU Lyon Sud; 🇫🇷 Lyon, France

Lille CHRU Hopital Claude Dieu; 🇫🇷 Lille, France

Montpellier CHU Saint Eloi; 🇫🇷 Montpellier, France

Rennes CHU Pontchaillou; 🇫🇷 Rennes, France

Rouen Centre Henri Becquerel; 🇫🇷 Rouen, France

Centro di Riferimento Oncologico di Aviano; 🇮🇹 Aviano, Italy

SC Ematologia Torino-Molinette; 🇮🇹 Torino, Italy

IOSI - Oncology Institute of Southern Switzerland; 🇨🇭 Bellinzona, Switzerland

Torino Università, Ematologia 1, AO Città della Salute e della Scienza; 🇮🇹 Torino, Italy